-
50% of patients with rheumatoid arthritis are misdiagnosed and mistreated, and multiple drugs can help achieve standard treatment
Time of Update: 2021-04-13
Starting from March 1 this year, the new JAK inhibitor drug for rheumatoid arthritis, Ailemin ( Baritinib tablets) have been successfully included in the new medical insurance for the treatment of moderate to severe active rheumatoid arthritis adult patients with poor efficacy or intolerance to one or more disease-improving anti-rheumatic drugs.
-
China's Allergy Care Initiative officially launched in 2021
Time of Update: 2021-04-13
Yesterday (March 31), Beijing Tongren Hospital took the lead in jointly launching an allergy care campaign with experts across the country to raise public awareness of allergic diseases.
-
NEJM: Upadacitinib is better than adalimumab in treating psoriatic arthritis
Time of Update: 2021-04-13
Researchers have recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments.
For patients with psoriatic arthritis, Upadacitinib treatment was better than placebo in terms of ACR20 response at week 12.
-
Scientists discover new ways to prevent excessive inflammatory activity
Time of Update: 2021-04-13
com/tags/%E9%A3%8E%E6%B9%BF%E6%80%A7%E5%85%B3%E8%8A%82%E7%82%8E/">Rheumatoid arthritisRecently, researchers from the Royal College of Surgeons in Ireland discovered that excessive inflammation can be suppressed by regulating the function of inflammatory cytokines in the immune system.
-
CHMP recommends approval of Benlysta for the treatment of active lupus nephritis
Time of Update: 2021-04-13
diagnosisGlaxoSmithKline (GSK) today announced that the European Medicines Management Agency (EMA) adopted a positive person with opinions and Drug Committee (CHMP), recommended that Benlysta (belimumab) Joint immune suppression therapy for active lupus nephritis (LN ).
-
Cell: Engineered immune cells can target and inhibit cancer cell metastasis
Time of Update: 2021-03-30
048Furthermore, the authors found that mice treated with GEMys cells had fewer metastatic cancers in the lungs and smaller tumors in the muscles.
048Furthermore, the authors found that mice treated with GEMys cells had fewer metastatic cancers in the lungs and smaller tumors in the muscles.
-
Analysis of Nature's Sub-Journal! Demystifying how organisms effectively distinguish the components of RNA and DNA? Or provide new ideas for the development of new antiviral drugs!
Time of Update: 2021-03-30
March 26, 2021 // - Recently, a research report entitled "The mechanism of the nucleo-sugar selection by multi-subunit RNA polymerases" was published in the international journal Nature Communications
-
Arthritis Rheumatol: DETECT algorithm can accurately predict the risk of pulmonary hypertension in patients with systemic sclerosis
Time of Update: 2021-03-30
Immune vascular pulmonary hypertension (PAH) is one of the main causes of death in SSc patientsThis study evaluated the prediction accuracy of the DETECT algorithm and the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines in the SSc cohort that received right heart catheterization (RHC) for pulmonary hypertension (PH) assessment .
-
The experimental drug ETC-159 may prevent certain tumors from becoming resistant to therapy by blocking key DNA repair mechanisms!
Time of Update: 2021-03-30
March 26, 2021 // - Recently, a research report entitled "WNT inhibition creates a BRCA-like state in Wnt-addicted cancer" published in the international journal EMBO Molecular Medicine , from Duke-Si
-
NEJM: Oral JAK inhibitor abroctinib for moderate to severe atopic dermatitis
Time of Update: 2021-03-30
Recently, researchers compared the JAK1 inhibitor Abroctinib with the interleukin-4 receptor monoclonal antibody Dupilumab for the treatment of atopic dermatitis.
Compared with placebo, abrocitinib can significantly improve the signs and symptoms of moderate to severe atopic dermatitis.
-
Flt3 inhibitor AML produces CR: talk about off-target...
Time of Update: 2021-03-29
Luxe was originally developed as a reversible BTK inhibitor and its main use is chronic leukemia, but so far it is still a substitute goalkeeper in this arena.
-
Father retires and mother resigns to guard children with rare diseases 24 hours a day to create miracles of life
Time of Update: 2021-03-29
5em; width: 2em; height: 2em; border-radius: 1em; margin-top: -1em; margin-left: -1.
5em; width: 2em; height: 2em; border-radius: 1em; margin-top: -1em; margin-left: -1.
More than three years ago, 5-month-old Mu Mu (pseudonym) was unfortunately diagnosed with spinal muscular atrophy at Hunan Provincial People's Hospital.
-
What changes will the introduction of IL-17A inhibitors into medical insurance bring to the AS "ecological circle"?
Time of Update: 2021-03-27
Picture: The scene of the 2nd Novartis Rheumatism and Immunity Summit Forum (Opening Session) 1 Extract from the conference: Innovative drugs are included in medical insurance to promote the clinical diagnosis and treatment of AS.
-
Science Sub-Journal: Revealing that radiotherapy and immunotherapy restrict tumor progression by removing extramedullary red blood cell precursor cells
Time of Update: 2021-03-27
The relevant research results were published in the journal Science Translational Medicine on February 24, 2021, with the title of the paper "Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity".
-
In cooperation with Xi’an Jiaotong University and other institutions, Jin Yan/Chen Xin and others have developed new materials to promote immune tolerance in mouse autoimmune models
Time of Update: 2021-03-27
Specifically, in the experimental model of colitis, IHM rapidly releases monocyte chemoattractant protein-1 after intravenous administration, which recruits activated T cells and then induces their apoptosis through Fas ligand on the surface of IHM.
-
How do scientists predict the risk of humans suffering from multiple diseases?
Time of Update: 2021-03-27
1038/s41551-020-00626-4Recently, in a research report published in the international journal Nature Biomedical Engineering, scientists from Singapore’s National Eye Center and other institutions have developed a new method using artificial intelligence technology to predict the risk of individuals suffering from cardiovascular disease.
-
Chen Xuewei's team from Sichuan Agricultural University published a review on the important regulatory role of non-coding RNA in the process of plant immunity
Time of Update: 2021-03-27
On March 20, 2021, Chen Xuewei’s team from the State Key Laboratory of Crop Gene Resources Discovery and Utilization of Sichuan Agricultural University was invited to write a review article titled Role of non-coding RNAs in plant immunity in the journal Plant Communications.
-
Latest research progress of CRISPR/Cas in February 2021
Time of Update: 2021-03-27
Mol Cell: New gene editing technology allows CRISPR-Cas9 to edit DNA sequentially doi:10.
A new CRISPR technology may revolutionize gene therapy to treat human genetic diseasesRecently, in a research report titled "In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice" published in the international journal Nature, scientists from the United States MIT and the Broad Institute reported a landmark gene therapy Milestone research results.
-
Scientists decode the kinetic changes of p53 in different tissues, or hope to help develop new anti-cancer therapies!
Time of Update: 2021-03-27
Scientists from Harvard Medical School and other institutions Through research, we show that revealing the dynamic properties of tumor suppressor proteins may help determine whether tissues will survive radiation.
-
A 29-year-old girl who took "herbal supplements" for half a year had rheumatism? | Wind list finalized
Time of Update: 2021-03-27
Seeing this, you may have some questions: Since drug-induced lupus (DIL) is considered, why the patient's kidney condition has not improved after stopping this herbal supplement?